Skip to main content
OpenTrials
Completed

NCT Number: NCT01445743

Immunogenicity and Safety of an Acellular DPT Vaccine During Pregnancy

That is a double-blind randomized trial with parallel control to demonstrate the safety and immunogenicity of acellular Tdap vaccine in pregnant mexican women. The general objective is to determine the safety and immunogenicity of acellular Tdap vaccine.

The experimental group will receive acellular Tdap vaccine and the control group will receive a placebo consisting of saline 0.9% Sodium Chloride solution, randomly assigned, which will be administered by the same route (intramuscular) and at the same dose (0.5 ml) that the vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–38 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Hospital Regional Materno Infantil de alta especialidad, Secretaria de Salud de Nuevo Leon

Guadalupe, Nuevo León, 66000, Mexico

About this study

Type of Study: Clinical, randomized, double-blind, parallel control study. Study Subjects: Pregnant women of 19-38years of age, gestational age of 12-24 weeks, low risk of obstetric complications (according to the Obstetric Risk Assessment Form), normal anatomic ultrasound performed in the second quarter of pregnancy and residence in Guadalupe, and Juarez cities in Nuevo Leon State.

The experimental group will receive acellular Tdap vaccine and the control group will receive a placebo consisting of saline (0.9% Sodium Chloride) solution, randomly assigned, which will be administered by the same route (intramuscular) and at the same dose (0.5 ml) that the vaccine by trained personnel.

For both groups, 6 blood samples will be taken. Women: Before and at least 4 weeks after the vaccine or placebo were administered, at hospital admission for delivery. Infant: collected at delivery (cord), 2, 4 and 6 months of age.

Immunogenicity will be compared in both groups by measuring the increase of three of the following antigen-specific antibodies: Pertussis toxin (PT), pertactin (PRN),and fimbriae 2 FIM 2).

Safety Assessment: Each pregnant will be observed at 30 minutes, 24 and 48 hours and one month after the application of the vaccine for side effects.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 to 38 years
  • Pregnancy between 22 and 32 weeks of gestation
  • Covered by Ministry of Health medical security
  • Definitive residency in Guadalupe and Benito Juarez cities
  • Pregnancy termination in the study's hospital.
  • At low risk for complication as determined by the obstetrical risk assessment form (ORAF)
  • Second trimester or later ultrasound with no significant abnormalities
  • Intend to be available for follow up visits and phone calls access through 6 months following delivery
  • Willing to give written informed consent

Exclusion criteria

  • Serious mental illness. (Schizophrenia, psychosis, major depression).
  • Serious underlying medical condition (e.g Degenerative diseases: Diabetes Mellitus,Hypertension and so on.
  • Current smoking or use of drugs.
  • Receipt of tetanus-diphtheria toxoid immunization within the past 2 years.
  • Be considered as a high risk pregnancy for serious obstetrical complication according to the local Obstetrical Risk Assessment Form.

Treatment and study plan

Biological/Vaccine: Tdap Vaccine

Biological

Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.

Other names: ADACEL

Primary outcomes

  1. Elevation of specific pertussis antibody levels in children of women who were administered the immunization

    Time frame: 18 months

    Elevation of at least three antibodies against either pertussis toxin (PT), pertactin (PRN), fimbrial proteins (FIM), or filamentous hemagglutinin (FHA).

Secondary outcomes

  1. Non interference of acellular vaccine in children

    Time frame: 18 months

    To demonstrate the acellular pertussis immunization non interference in the effective development of pertussis antibodies in children at 2, 4, and 6 months of age.

Sponsors and collaborators

Lead sponsor

Hospital Universitario Dr. Jose E. Gonzalez

Other

Registry information

Official study title

Immunogenicity and Safety of an Acellular DPT Vaccine in Pregnant Women in Nuevo Leon, Mexico

Important dates

Study start
2011
Primary completion
2012
Study completion
2014
First posted
Oct 4, 2011
Registry last updated
Feb 14, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.